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ABSTRACT
The drug classification scheme of the World Health
Organization (WHO) [Anatomical Therapeutic Chem-
ical (ATC)-code] connects chemical classification
and therapeutic approach. It is generally accepted
that compounds with similar physicochemical
properties exhibit similar biological activity. If this
hypothesis holds true for drugs, then the ATC-code,
the putative medical indication area and potentially
the medical targetshould be predictable on thebasis
of structural similarity. We have validated that the
prediction of the drug class is reliable for WHO-
classified drugs. The reliability of the predicted
medical effects of the compounds increases with a
rising number of (physico-) chemical properties
similar to a drug with known function. The web-
server translates a user-defined molecule into a
structural fingerprint that is compared to about
6300 drugs, which are enriched by 7300 links to
molecular targets of the drugs, derived through text
mining followed by manual curation. Links to the
affected pathways are provided. The similarity to the
medical compounds is expressed by the Tanimoto
coefficient that gives the structural similarity of two
compounds. A similarity score higher than 0.85
results in correct ATC prediction for 81% of all
cases. As the biological effect is well predictable,
ifthestructuralsimilarityissufficient,theweb-server
allows prognoses about the medical indication
area of novel compounds and to find new leads for
known targets.
Availability: the system is freely accessible at http://
bioinformatics.charite.de/superpred. SuperPred can
be obtained via a Creative Commons Attribution
Noncommercial-Share Alike 3.0 License.
INTRODUCTION
The accessibility of large compound databases has
changed from exclusive inhouse databases of large
pharmaceutical companies to publicly available sources
(1). At this time several million diﬀerent compounds can
be obtained from diﬀerent vendors (2). About 7000 drugs
currently exist and there are about 480 validated targets
that are addressed (3). There are estimations about the
number of medical targets between 2200 and 3000 that
favour interactions with drug-like chemical compounds
(4). To map these medical targets onto medical indication
areas a classiﬁcation scheme is needed.
Currently, the most commonly used classiﬁcation
system for drugs is the Anatomical Therapeutic Chemical
(ATC) classiﬁcation system. This scheme is recommended
by the World Health Organization (WHO) for all global
drug utilization studies and categorizes drug substances at
diﬀerent levels according to application area, therapeutic
properties, chemical and pharmacological properties (5).
A challenging aim is the mapping of the available
compounds onto about 850 ATC-classes. The progress in
understanding the mechanisms of action of a vast majority
of drugs gives the opportunity to narrow down the gap
between the medical indications and elucidation of drug
eﬀects at the molecular level. The relation between the
structure of a compound and its biological activity was
well investigated in some systematic analyses (6–8). It
could be shown that a Tanimoto coeﬃcient of >0.85
indicates that two molecules have similar activities (8).
Based on this principle, it should be possible to predict
medical indication areas for unclassiﬁed chemical com-
pounds in case of suﬃcient structural similarity. A method
based on the similar property principle (9) for predicting
activity spectra of substances was described by Lagunin
(10) and conﬁrmed by several experiments (11,12). The
PASS application is available at http://www.ibmc.msk.ru/
PASS. Furthermore, new medical indication areas for
approved drugs or drug candidates can be found by
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put into drug repositioning (13,14). To discriminate
between drugs and nondrugs, the use of property distri-
butions and (physico-) chemical descriptors is already
used successfully (15,16). The increased knowledge about
drug-target-pathway relations and the integration of
molecular similarity with property distribution allow
improved structure–function prediction. Here, we present
a publicly available web-server to predict medical indica-
tion areas based on properties and similarity of chemical
compounds.
METHODS
Data setforthe web-server
The web-server called SuperPred was created for recogni-
tion of as many drug classes as possible. For this reason,
the number of medical compounds was enlarged to about
6300. The calculated ﬁngerprints from the 2500 com-
pounds of the SuperDrug database were used for a further
structural screening against the SuperTarget database
(17). In this way, 3800 additional compounds were
detected that are structurally very similar to drugs and
resulted in Tanimoto coeﬃcients of at least 0.85. These
putative drugs are most likely candidates for having the
same mode of action, binding to the same target/enzyme
and being assigned to the same medical indication as the
WHO-classiﬁed drugs. In order to allow the examination
of the drug eﬀect on a molecular level, information about
the target proteins was extracted from literature and was
provided for half of the drugs (17).
Reduceddata setforprediction evaluation
For the purpose of statistical evaluation of the prediction
accuracy, a subset consisting of 1035 drugs was utilized.
The members of the subset were chosen according to the
following rules: First, every drug having more than one
indication was removed; then each included ATC-group
had to consist of at least 3 molecules and last, to eliminate
outliers, the drugs within one ATC-group were not
allowed to deviate more than 1.5-fold from the average
Tanimoto score of the group. Furthermore, ATC-codes
with very similar indications were organized into ATC-
classes. For instance, ‘corticosteroids, moderately potent’
(ATC: D07AB), ‘corticosteroids, potent’ (ATC: D07AC),
‘corticosteroids, very potent’ (ATC: D07AD) and ‘corti-
costeroids, plain’ (ATC: S01BA) were combined to form
the ATC-class ‘corticosteroids’ (see website and Supple-
mental material).
Prediction
The prediction was carried out by the combination of
physicochemical property analyses and similarity search-
ing. The prediction of the ATC-class was performed by
the assignment of the compound to the ATC-class of the
most similar drug and property distribution. The predic-
tion accuracy was determined by the leave-one-out cross-
validation method.
Physicochemical properties
Lipinski’s Rule of Five (18) is a general accepted standard
for oral applicable drugs. The rule describes molecular
properties important for a drug’s absorption, distribution,
metabolism and excretion in the human body. It is stated
that an orally active drug has not more than 5 hydrogen-
bond donors, not more than 10 hydrogen-bond acceptors,
a molecular weight below 500g/mol and a logP less than 5.
These properties and several more were calculated for
each drug in SuperPred. The distributions of the proper-
ties’ values were saved in the database for each ATC-
group and -class. In this way, the range of property values
is comparable with the query.
Similarity searches
To calculate the similarity between two compounds, their
structural ﬁngerprints, generated by Chemistry Develop-
ment ToolKit (CDK) (http://almost.cubic.uni-koeln.de/
cdk/), were used. Structural ﬁngerprints are bit-vectors
encoding for the chemical and topological features of
small molecules. The similarity is determined by the
Tanimoto coeﬃcient (19):
T ¼
Nab
Na þ Nb   Nab
where Na is the number of bits set to 1 in compound a, Nb
is the number of bits set to 1 in compound b and Nab is the
number of bits common to both, compounds a and b.
Input and output options
There are three ways to start a query with a molecule not
included in the database:
  Enter SMILES (Simpliﬁed Molecular Input Line Entry
System)
  Draw a molecule using Marvin Sketch
  Upload a MOL ﬁle using Marvin Sketch
Medical compounds can be retrieved through an
expandable ATC-tree, by name, synonym, ATC-code or
via known target (name, Uniprot-ID).
The output is a structured table, listing predictions
(ATC-codes including conﬁdence interval) containing
similarity scores, compound-IDs, molecular structure
visualized by Marvin View, target information and
physicochemical property intervals of the ATC-group
and of the query compound. The score and the color
indicate the power of the prediction visualized.
RESULTS
Prediction results
The prediction accuracy is determined by the fraction of
correct ATC-class predictions and amounts 67.6%. The
distribution of the fractions of correctly predicted indica-
tions is shown in Table 1. For a Tanimoto coeﬃcient
>0.85 an accuracy of 80.6% is accomplished. A cumula-
tive recall graph is shown in Figure 1. The graph shows the
fraction of right predictions of ATC-classes in dependency
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molecules the recall gains to about 80% and with 20
retrieved molecules a recall of about 90% is achieved.
For the reduced data set of 1035 drugs, the recall is
cumulated for one retrieved drug up to twenty retrieved
drugs. With three retrieved molecules the recall gains to
about 80% and with 20 retrieved molecules a cumulative
recall of about 90% is achieved.
Case study
Besides leave-one-out cross-validation statistics, the pre-
diction method was proved by a number of compounds
extracted from the SuperTarget database as well as
compounds experimentally tested against tumor-cell line
assays.
Starting point for the ﬁrst screening was Enalapril, an
ACE-inhibitor, that is used in treatment of hypertension
and congestive heart failure. SuperPred identiﬁes six
putative drugs having a suﬃcient similarity to Enalapril
indicated by a green color in the result table (Tanimoto
coeﬃcient >0.8). An inspection of the referenced literature
via the Pubchem-database denoted a similar medical eﬀect
for all of them. Table 2 shows exemplarily the names of
three of the six putative compounds and the associated
reference that describes the medical eﬀect of inhibiting the
angiotensin-converting enzyme.
The National Cancer Institute Developmental
Therapeutics Program (DTP) has screened about 100000
compounds against a panel of 60 human tumor-cell lines.
The results are available on the DTP web site (http://
dtp.nci.nih.gov/). The growth inhibition (GI50) and lethal
dose (LD50) of the compounds are also retrievable.
Application:
(i) NCI-compound (NSC: 600221) is a screening hit
with unveriﬁed target. This compound shares a
Tanimoto coeﬃcient of 0.92 with the compound
Paclitaxel and therefore, it is predicted to be an
antineoplastic agent targeting Tubulin.
(ii) Enalapril is a well-known ACE-inhibitor. The
compound Sch31846 has a similarity of 95% and
is supposed to be an ACE-inhibitor, too.
Isolated compounds of the comprehensive tumor-
related information resource of the NCI were extracted
and screened against the approved drugs included in
SuperPred. Many of the screening candidates were charac-
terized by a high physicochemical similarity to well-anno-
tated anti-cancer drugs. For instance, the compound NSC
600221 (Table 2) and the antineoplastic agent Paclitaxel
hold a Tanimoto coeﬃcient of 0.91. Both compounds are
Table 2. Compounds identiﬁed with SuperPred and similar to Enalapril and NSC 600221, respectively
Name of the
compound
Tanimoto
coeﬃcient
Medical function Target protein Reference
Enalapril 100.00 ACE-inhibitor Angiotensin-converting enzyme (22)
Sch 31846
a 94.57 ACE-inhibitor (predicted) Angiotensin-converting enzyme (predicted) (23)
Delapril hydrochloride 83.84 ACE-inhibitor (predicted) Angiotensin-converting enzyme (predicted) (24)
Hoe 065
b 81.90 ACE-inhibitor/increasing central
cholinergic activity (predicted)
Angiotensin-converting enzyme (predicted) (25)
NSC 600221
c 100.00 Antineoplastic agent Tubulin (predicted) http://dtp.nci.nih.gov
Paclitaxel 91.62 Antineoplastic agent Tubulin beta-1chain (26)
a(2S,3aS,7aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl) hexahydro-2 indolinecarboxylic acid, 1-ethyl ester, monohydrochloride.
bCyclopenta(c)pyrrole-1-carboxylic acid, 2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, octyl ester, (1S-(1-alpha,2-
(R
 (R
 )),3a-beta,6a-alpha))-, (Z)-2-butenedioate (1:1).
cBeta-Phenylalanine, N-benzoyl-2-[[(2-carboxyethyl) carbonyl]oxy]-, 6,12b-diacetoxy-12-(benzoyloxy)-2a,3,3a,4,5,6,9, 10,11,12,12a,12b-dodecahydro-
4,11- dihydroxy-4a,8,13, 13-tetramethyl-5-oxo-7,11-methano- 1H-cyclodeca[3,4]benz[1, 2-b]oxet-9-yl ester.
Figure 1. Cumulative recall for ATC-recognition relative to rank of
retrieval.
Table 1. Distribution of the fractions of correctly predicted indications
Range of Tanimoto
coeﬃcient
Numbers of
hits/misses
Fraction
of hits
0.4–0.5 5/18 21.7
0.5–0.6 18/27 40.0
0.6–0.7 40/60 40.0
0.7–0.8 93/84 52.5
0.8–0.9 171/58 74.7
0.9–1.0 367/79 82.3
0.0–1.0 700/335 67.6
For the reduced data set of 1035 drugs, 700 right and 335 wrong
predictions are investigated. In detail: a similarity score of 90–100%
speciﬁes the correct ATC-class in about 82% (367 right and 79 wrong
predictions). A hit/miss-rate of about 3/1 is achieved for similarity
scores of 70% and higher.
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proliferation of cancer cells, the GI50-values of both
compounds were analyzed with COMPARE, a web
accessible tool for investigating mechanisms of cell GI
(20). The ability to inhibit the growth of the diverse set of
cell lines was highly similar and was indicated by a
correlation coeﬃcient of 0.87 calculated by COMPARE.
The high correlation coeﬃcient even allowed predictions
about the target protein of NSC 600221 (21). As Paclitaxel
inhibits microtubule formation by binding to tubulin, the
same target came into question for NSC 600221.
CONCLUSION
The SuperPred web-server was created for predicting
medical indications for chemical compounds. The combi-
nation of physicochemical property and similarity search-
ing provides the possibility to detect new biologically
active compounds and novel targets for drug-like com-
pounds. SuperPred can be applied for drug repositioning
purposes, too. A further intention of SuperPred is to ﬁnd
side eﬀects elicited by drugs caused through oﬀ-target hits.
The use of the web-server is free for all academics.
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